The objective of this project is to advance the technological maturity of previous research.
Mastitis is a common and costly infection in dairy cows, affecting both production and animal welfare. Current treatments rely on traditional antibiotics. Due to the development of multiple resistances in certain microorganisms responsible for these infections, there is an urgent need for more effective and safer solutions for animals. This project aims to develop new molecules suitable for intramammary administration and to meet Canada’s performance, stability, and safety requirements.
The team covers all stages: chemical synthesis, laboratory testing to assess antimicrobial activity and safety, and validation in animal models and cows. The work integrates organic chemistry, microbiology, and pharmacology to design stable, bioavailable formulations. Ultimately, this project could provide producers with reliable, innovative treatments to reduce economic losses and improve animal health while limiting the risks associated with traditional antibiotics.
